Frost & Sullivan
AUGUST 28, 2024
BiBo Pharma is breaking capacity barriers and reducing antibody drug production costs from the international average of hundreds of dollars to just $10 per gram, offering disruptive solutions to global biopharmaceutical companies. times compared to the current 15,000L (total volume) standard in large-scale biopharmaceutical production.
Frost & Sullivan
MAY 12, 2021
May 12, 2021 – The biopharmaceutical industry is facing its biggest test in recent times. A rise in new disease outbreaks, the urgency to launch innovative therapies, and new constructs such as multi-valent antibodies are compelling biopharmaceutical companies to adopt new manufacturing approaches. SANTA CLARA, Calif. –
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Peter Simoons
JANUARY 14, 2024
Head of Alliances, Global Biopharmaceutical Company What Have I Been Reading: “ Partnering: Forge the Deep Connections That Make Great Things Happen ”* by Jean Oelwang Why Is It Relevant? Being a little biassed I expected this book to be about Alliances & Partnerships as we know them.
Jake Jorgovan
NOVEMBER 27, 2023
Biopharmaceutical Consulting: Supporting every aspect of the biopharma value chain, including R&D, operations, manufacturing, commercialization, and mergers and acquisitions (M&A). Their services are utilized across multiple industries including construction, banking, retail, education, and healthcare.
Jake Jorgovan
NOVEMBER 15, 2023
However, they operate particularly within the Montreal-Toronto-Boston triangle.
Frost & Sullivan
APRIL 3, 2024
Fuelling Growth: Strategic Investments, Acquisitions, and Expansions Samsung Biologics unveiled plans to expand capacity and geographic reach by initiating the construction of Bio Campus II with a $6 billion investment scheduled to begin operations in 2025 while completing its CGMP antibody-drug conjugate manufacturing facility within 2024.
Expert insights. Personalized for you.
52 
Let's personalize your content